Cravit IV, administered once daily, is classified as a respiratory quinolone suited to treat respiratory tract infections.
Daiichi said that 100mg Cravit tablets were approved in Japan for sale in December 1993 and in July 2009.
In Japan, orally administered 100mg Cravit tablets were approved for sale in December 1993 and in July 2009, the once-daily administration with 500mg Cravit was approved in line with the world standard dosage regimen.
Now, Daiichi Sankyo has further expanded treatment options with the addition of Cravit IV.